RxDoctor Payments Data

Erik Krause, DO

Neurology · Austin, TXNPI 1194131888

Payments from drug & device makers

$9,149in general payments, 2019–2025

Across 154 payments — averaging $59.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Abbott$1K
  • Amneal Pharmaceuticals LLC$164
  • Boston Scientific$151
  • AbbVie$128
  • MDD US Operations, LLC$103
  • plus $355 from 10 others

What the payments were for

  • Grants$6,25068%
  • Food & beverage$2,89932%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,149 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$222,989
Medicare patients
401
Services billed
17,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine58$556,855
IngrezzaValbenazine Tosylate43$369,591
RytaryCarbidopa/Levodopa192$366,024
AustedoDeutetrabenazine18$287,936
NuplazidPimavanserin Tartrate37$175,847
GocovriAmantadine Hcl35$131,435
BotoxOnabotulinumtoxina49$70,331
Nurtec OdtRimegepant Sulfate18$30,849
Carbidopa-LevodopaCarbidopa/Levodopa904$29,222
Rasagiline Mesylate96$13,855
Propranolol Hcl ErPropranolol Hcl165$7,519
AmantadineAmantadine Hcl141$6,211
Rivastigmine32$5,751
Carbidopa-Levodopa ErCarbidopa/Levodopa193$5,339
Primidone88$4,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$88$844,79176 claims
Amneal Pharmaceuticals LLCRytary$164$366,024192 claims
Acadia Pharmaceuticals IncNuplazid$15$175,84737 claims
MDD US Operations, LLCGocovri$103$131,43535 claims
AbbVieBotox$128$70,33149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →